Efficacy of placental derived allografts and standard of care in the treatment of nonhealing diabetic foot ulcers using matched controls: a randomized controlled trial.

Diabetic foot ulcers (DFUs) are a severe complication of diabetes, contributing to high morbidity, risk of amputation, premature mortality, and substantial healthcare costs. Standard of care (SOC), including debridement, offloading, infection control, and moisture balance, remains the foundation of DFU treatment; however, many ulcers fail to achieve complete closure with SOC alone. Placental-derived allografts, classified as cellular, acellular, and matrix-like products (CAMPs), provide a biologically active extracellular scaffold rich in growth factors and struc-tural proteins that support angiogenesis, cellular migration, and control of inflammation.

Chronic wounds such as pressure ulcers (PUs) impose substantial physical, emotional and financial strain on patients and healthcare systems.1

The development and persistence of PUs are exacerbated by multiple comorbidities: cardiovascular disease, diabetes, renal dysfunction, malnutrition, and immobility, all of which impair healing despite standard preventative and therapeutic efforts.2

Globally, PUs are recognized as a major component of the chronicwound burden and pose significant strain on healthcare resource